Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells.
Songqiang XieJingxuan PanPublished in: British journal of pharmacology (2017)
PD-0332991 can elicit a strong antitumour activity against ESCC growth and metastasis and may be a promising candidate drug for the treatment of patients with ESCC. Our results warrant a clinical trial to further evaluate the efficacy of PD-0332991 in ESCC patients, even those with metastasis.
Keyphrases
- squamous cell carcinoma
- clinical trial
- end stage renal disease
- ejection fraction
- induced apoptosis
- cell cycle arrest
- chronic kidney disease
- dna damage
- prognostic factors
- emergency department
- cell cycle
- endothelial cells
- cell proliferation
- signaling pathway
- open label
- combination therapy
- tyrosine kinase
- endoplasmic reticulum stress
- locally advanced
- phase ii
- stress induced
- adverse drug
- electronic health record